<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24207" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Leukemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chennamadhavuni</surname>
            <given-names>Adithya</given-names>
          </name>
          <aff>Sutter health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lyengar</surname>
            <given-names>Varun</given-names>
          </name>
          <aff>Brown University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukkamalla</surname>
            <given-names>Shiva Kumar R.</given-names>
          </name>
          <aff>Presbyterian Healthcare Services</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shimanovsky</surname>
            <given-names>Alex</given-names>
          </name>
          <aff>Brown University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adithya Chennamadhavuni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Varun Lyengar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alex Shimanovsky declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24207.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Leukemia is a heterogeneous group of hematologic malignancies that arise from the dysfunctional proliferation of developing leukocytes. It is classified as either acute or chronic based on the rapidity of proliferation and as myelocytic or lymphocytic based on the cell of origin. Treatment depends on the type of leukemia but generally involves chemotherapy. Multiple genetic and environmental risk factors are identified in the development of leukemia. According to the Surveillance, Epidemiology, and End Results (SEER) database, there are 61,090 estimated new cases of leukemia in 2021, accounting for 3.2% of all new cancer cases, making leukemia the 10th most common cancer in the United States. This activity describes the evaluation and management of leukemia and reviews the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the epidemiology of leukemia.</p></list-item><list-item><p>Review the appropriate evaluation of leukemia.</p></list-item><list-item><p>Outline the management options available for leukemia.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication when treating patients with leukemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24207">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24207.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The production of abnormal leukocytes defines leukemia as either a primary or secondary process. They can be classified as acute or chronic based on the rapidity of proliferation and myeloid or lymphoid based on the cell of origin.&#x000a0;Predominant subtypes are acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), involving the myeloid lineage; acute lymphoblastic leukemia (ALL); and chronic lymphocytic leukemia (CLL), involving the lymphoid chain. Other less common variants, such as mature B-cell and T-cell leukemias, and NK cell-related leukemias, to name a few, arise from mature white blood cells. However, with the advent of next-generation sequencing (NGS) and the identification of various biomarkers, the World Health Organization (WHO) classification was updated in 2016, bringing multiple changes to the traditional classification for acute leukemias and myeloid neoplasms.<xref ref-type="bibr" rid="article-24207.r1">[1]</xref>&#x000a0;GLOBOCAN, a global observatory for cancer trends, showed a global incidence of 474,519 cases, with 67,784 in North America. The Age-Standardized Rates are around 11 per 100,000, with a mortality rate of approximately 3.2.<xref ref-type="bibr" rid="article-24207.r2">[2]</xref></p>
        <p>Many genetic risk factors have been identified, such as Klinefelter and Down syndromes, ataxia telangiectasia, Bloom syndrome, and telomeropathies such as Fanconi anemia, dyskeratosis congenita, and Shwachman-Diamond syndrome; germline mutations in RUNX1, CEBPA, to name a few. Viral infections associated with Epstein Barr virus, human T-lymphotropic virus, ionizing radiation exposure, radiation therapy, environmental exposure with benzene, smoking history, history of chemotherapy with alkylating agents, and topoisomerase II agents have also been implicated in the development of acute leukemias. Symptoms are nonspecific and can include fever, fatigue, weight loss, bone pain, bruising, or bleeding. Definitive diagnoses often require bone marrow biopsy, the results of which help the hematologists and stem cell transplant physicians regarding the selection of treatment options ranging from chemotherapy to allogeneic stem cell transplantation. The prognosis is variable depending on the leukemia subtype in question.</p>
        <p><bold>Acute vs. chronic myeloid leukemia:</bold> Blasts,&#x000a0;which are&#x000a0;immature and&#x000a0;dysfunctional cells, normally make up 1% to 5% of marrow cells. Acute leukemias are characterized by greater than 20% blasts in the peripheral blood smear or on bone marrow leading to&#x000a0;a more rapid onset of symptoms. In contrast, chronic leukemia has less than 20% blasts with&#x000a0;a relatively chronic onset of symptoms. The accelerated/blast phase is a transformation of chronic myeloid leukemia into an acute phase with a significantly higher degree of blasts.<xref ref-type="bibr" rid="article-24207.r1">[1]</xref><xref ref-type="bibr" rid="article-24207.r3">[3]</xref><xref ref-type="bibr" rid="article-24207.r4">[4]</xref></p>
        <p>As such, the four major subtypes of leukemia are:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acute lymphoblastic leukemia (ALL):</bold> ALL is seen in patients with the blastic transformation of B and T cells. It is the most common leukemia in the pediatric population, accounting for up to 80% of cases in this group vs. 20% of cases in adults. Treatment among adolescents and young adults is predominantly inspired by pediatric regimens with better survival rates.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Acute myelogenous leukemia (AML):</bold> AML is characterized by greater than 20% myeloid blasts and is the most common acute leukemia in adults. It is the most aggressive cancer with a variable prognosis depending upon the molecular subtypes.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Chronic lymphocytic leukemia (CLL):</bold> CLL occurs&#x000a0;from the proliferation of monoclonal lymphoid&#x000a0;cells. Most cases occur in people between the ages of 60 and 70. CLL is considered an indolent disease, for the most part, meaning not all patients with a diagnosis will need to start treatment until symptomatic from the disease.</p>
          </list-item>
          <list-item>
            <p><bold>Chronic myelogenous leukemia (CML):</bold>&#x000a0;CML typically arises from reciprocal translocation and fusion of BCR on chromosome 22 and ABL1&#x000a0;on chromosome 9, resulting in dysregulated tyrosine kinase on chromosome 22 called the Philadelphia (Ph) chromosome.&#x000a0;This, in turn, causes a monoclonal population of dysfunctional granulocytes, predominantly neutrophils, basophils, and eosinophils.<xref ref-type="bibr" rid="article-24207.r1">[1]</xref><xref ref-type="bibr" rid="article-24207.r3">[3]</xref><xref ref-type="bibr" rid="article-24207.r5">[5]</xref><xref ref-type="bibr" rid="article-24207.r6">[6]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24207.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Multiple genetic and environmental risk factors are identified in the development of leukemia.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Exposure to ionizing radiation is associated with an increased risk of multiple leukemia subtypes.<xref ref-type="bibr" rid="article-24207.r7">[7]</xref><xref ref-type="bibr" rid="article-24207.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Exposure to benzene is a risk factor for leukemia in adults, particularly AML.<xref ref-type="bibr" rid="article-24207.r9">[9]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Previous exposure to chemotherapy, especially alkylating agents and topoisomerase II inhibitors, increases the risk for acute leukemia later in life.<xref ref-type="bibr" rid="article-24207.r7">[7]</xref><xref ref-type="bibr" rid="article-24207.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>A history of any hematologic malignancy is a risk factor for subsequently developing another subtype of leukemia.<xref ref-type="bibr" rid="article-24207.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Viral infections (e.g., human T-cell leukemia virus, Epstein Barr virus) are linked with subtypes of ALL.<xref ref-type="bibr" rid="article-24207.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Several genetic syndromes (e.g., Down syndrome, Fanconi anemia, Bloom syndrome, Li-Fraumeni syndrome) are associated with an increased risk of AML and ALL.<xref ref-type="bibr" rid="article-24207.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24207.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>GLOBOCAN, which is a global observatory for cancer trends, showed a global incidence of 474,519 cases, with 67,784 in North America. The age-standardized rates are around 11 per 100,000, with a mortality rate of about 3.2. ALL and AML, which are important diseases in both childhood and adulthood, have bimodal age distributions, with CML and CLL mostly in the older age groups. According to the Surveillance, Epidemiology, and End Results (SEER) database, there are&#x000a0;61,090 estimated new cases&#x000a0;of leukemia in 2021, accounting for 3.2% of all new cancer cases, making leukemia the 10th most common cancer in the United States. Estimated deaths are about&#x000a0;23,660, which comprises 3.9% of all cancer deaths.&#x000a0;Since 2006, the incidence of&#x000a0;the disease has increased by an average of 0.6% per year,&#x000a0;while&#x000a0;the mortality has decreased by an annual average of 1.5%.<xref ref-type="bibr" rid="article-24207.r6">[6]</xref><xref ref-type="bibr" rid="article-24207.r7">[7]</xref></p>
      </sec>
      <sec id="article-24207.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Leukemia occurs due to the malignant&#x000a0;transformation of pluripotent (i.e., it can give rise to both myeloid and lymphoid precursors) hematopoietic stem cells. Rarely, it can also involve a more committed stem cell with limited self-renewal capacity. In acute leukemias, these malignant cells are generally immature, poorly differentiated, abnormal leukocytes (blasts) that can either be lymphoblasts or myeloblasts. These blasts can undergo clonal expansion and proliferation, leading to replacement and interference with the development and function of normal blood cells, leading to clinical symptoms.&#x000a0;</p>
        <p>
<bold>Acute Leukemia</bold>
</p>
        <p>In ALL, chromosomal translocation or abnormal chromosome numbers can lead to mutations in precursor lymphoid cells leading to lymphoblasts. Common mutations include t(12;21) and t(9;22). In AML, chromosomal translocations, rearrangements, and gain or loss of chromosomes can lead to mutations and abnormal production of myeloblasts. One important translocation is t(15;17), which leads to the fusion of retinoic acid receptor alpha (RARA) and a promyelocytic leukemia transcription factor (PML). This leads to the development of acute promyelocytic leukemia, which can present with hallmarks of disseminated intravascular coagulation&#x000a0;and need emergent treatment with all-trans retinoic acid.</p>
        <p>
<bold>Chronic Leukemia</bold>
</p>
        <p>Chromosomal abnormalities in hematopoietic stem cells that are precursors to leucocytes are the most common cause of chronic leukemia. Examples of abnormalities are deletions, translocations, or extra chromosomes. In CML, mutations mainly affect granulocytes (most commonly the t(9;22) translocation), and in CLL, they primarily affect lymphocytes (especially B lymphocytes). Unlike acute leukemias, in chronic leukemias, cells are partially mature. These partially mature cells do not function effectively and divide too quickly. They accumulate in the peripheral blood and lymphoid organs, which can lead to anemia and thrombocytopenia, and leukopenia.&#x000a0;</p>
      </sec>
      <sec id="article-24207.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>
<bold>Acute Leukemia</bold>
</p>
        <p>In acute leukemia, the peripheral blood or bone marrow is characterized by&#x000a0;more than 20% blasts. However, regardless of the blast percentage, patients with t(8;21)(q22;q22), RUNX1-RUNX1T1, inv(16)(p13.1q22) or t(16;16)(p13.1;q22), CBFB-MYH11 or t(15;17)(q24.1;q21.1), PML-RARA, are considered and treated as acute leukemia. There is usually increased cellularity noted on bone marrow biopsy that is packed with blasts and a variable&#x000a0;number of granulocytic or monocytic cells&#x000a0;and erythroid precursors. Traditional markers included in the evaluation are CD7, CD11b, CD13, CD14, CD15, CD16, CD33, CD34, CD45, CD56, CD117, HLA-DR. Also, either peripheral smear or bone marrow aspirate is sent for a mutation panel of multiple genes with&#x000a0;therapeutic and prognostic implications, such as&#x000a0;ASXL1, CEBPA, DNMT3A, FLT3, IDH1, IDH2, NPM1, RUNX1, and&#x000a0;TP53, to mention a few.&#x000a0;</p>
        <p>There is also increased bone marrow cellularity in ALL, composed of B and T lymphoblasts (with small nucleoli,&#x000a0;dispersed&#x000a0;chromatin, cleaved and irregular nuclei with undetectable cytoplasm). Common T-cell lymphoid immunostains include TdT,&#x000a0;CD2, CD3, CD5, and CD7. Common B-cell lymphoid immunostains include HLA-DR, CD10, CD19, CD22, CD79a, PAX5, and CD20. There should not be any myeloid markers, such as myeloperoxidase (MPO), to confirm the diagnosis of the pure lymphoid lineage. Mixed phenotype acute leukemia (MPAL) has&#x000a0;both myeloid and lymphoid markers&#x000a0;but is a rare entity. Cytogenetics evaluation&#x000a0;for Ph chromosome status and Ph-like translocation is a must as newer therapeutic agents are now incorporated into treatment algorithms.<xref ref-type="bibr" rid="article-24207.r13">[13]</xref></p>
        <p>
<bold>Chronic Leukemia</bold>
</p>
        <p>The white blood cell count in chronic leukemia is often elevated, with a smear suggestive of&#x000a0;significant left shift/granulocyte predominance. Such a picture is commonly seen during the acute illness phase, but if such a picture persists upon repeat labs, CML should be evaluated.<bold>&#x000a0;</bold>In CML, the translocation t(9;22) can be diagnosed by fluorescence in-situ hybridization (FISH) on peripheral blood. Bone marrow biopsy is not necessary for diagnosis, but if done, it will usually show 100% cellular marrow with increased granulocyte precursors, basophils, eosinophils, and&#x000a0;occasional&#x000a0;monocytes.</p>
        <p>In CLL, the white cell count is elevated, with mostly CD5+ and CD23+ B-lymphocytes. The clonal lymphocyte population has to be greater than 5,000/mcL for diagnosis. If the clonal lymphocyte population is less than 5,000/mcL, the&#x000a0;entity is termed&#x000a0;monoclonal B cell lymphocytosis of undetermined significance. Flow cytometry is often diagnostic. Patients would need evaluation for del(17p) and&#x000a0;<italic toggle="yes">TP53</italic>&#x000a0;mutation status, immunoglobulin heavy chain variable region (IGHV) gene mutation status, del(11q), del(13q), and trisomy 12 evaluation, which can help in selecting appropriate treatment regimens.<xref ref-type="bibr" rid="article-24207.r14">[14]</xref></p>
      </sec>
      <sec id="article-24207.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Acute Leukemia</bold>
</p>
        <p>Acute leukemia tends to present non-specifically, although the most common presenting features include fever, lethargy, and bleeding. Hepatosplenomegaly, lymphadenopathy, and musculoskeletal symptoms (especially involving the spine and long bones) can also be clues to the diagnosis. Adults may also have more prominent anemia-related symptoms, such as shortness of breath, or symptoms related to thrombocytopenia, such as excessive bruising or increased bleeding tendency. Patients with acute promyelocytic leukemia (APL), which is associated with disseminated intravascular coagulation-type symptoms, can present with mucosal bleeding, including gum bleeds, nosebleeds, or menorrhagia.&#x000a0;</p>
        <p>
<bold>Chronic Leukemia</bold>
</p>
        <p>Chronic leukemia subtypes occur almost exclusively in adults. Many patients are asymptomatic at the time of diagnosis, identified only incidentally after marked leukocytosis is discovered on a complete blood count (CBC) performed for another reason. Hepatosplenomegaly and lymphadenopathy can be appreciated in some cases, while bleeding and bruising are less common, presenting features relative to acute leukemia subtypes.<xref ref-type="bibr" rid="article-24207.r15">[15]</xref></p>
      </sec>
      <sec id="article-24207.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The workup of leukemia is very involved, and multiple tests are needed to confirm a diagnosis and, subsequently, to stage the disease. Helpful initial studies include a CBC,&#x000a0;comprehensive&#x000a0;metabolic panel, liver function tests (LFT), and coagulation panel, which are often followed by a peripheral blood smear evaluation and a bone marrow biopsy and aspiration.&#x000a0;</p>
        <p>On rare occasions, leukemia can be diagnosed on histology alone. For example, AML is characterized by the presence of Auer rods (red-staining, needle-like bodies seen in the cytoplasm of myeloblasts) on a peripheral smear. In most other cases, more detailed analyses&#x000a0;with flow cytometry, cytogenetics, and FISH testing are required to distinguish between subtypes.<xref ref-type="bibr" rid="article-24207.r16">[16]</xref></p>
        <p>A bone marrow aspiration and biopsy are often required for the diagnosis of acute leukemias. For chronic leukemias, peripheral blood evaluation is often enough, and an invasive bone marrow biopsy may not be needed. For example, CML can be diagnosed by looking for BCR-ABL fusion protein on peripheral blood FISH analysis. CLL can be diagnosed by looking for a monoclonal B-cell population through peripheral blood flow cytometry.</p>
      </sec>
      <sec id="article-24207.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Patients with leukemia should be referred to a hematologist-oncologist to initiate treatment. Therapy varies significantly based on the leukemia subtype and patient factors (e.g., age, comorbid conditions).&#x000a0;Acute leukemias are treated predominantly as an in-patient needing significant support, frequent monitoring of vitals, and assessment for opportunistic infections and electrolyte imbalances.&#x000a0;The predominant challenge at the time of diagnosis of acute myeloid leukemia is to&#x000a0;identify the possibility of&#x000a0;APL, which&#x000a0;has a significantly different treatment compared to the rest of AML.</p>
        <p><bold>APL: </bold>APL patients typically present with bleeding diathesis with increased coagulation parameters (elevated PT, aPTT) and low fibrinogen. Peripheral smear shows a predominance of myeloid blasts with Auer rods. It is important to start the treatment with ATRA (all-trans-retinoic acid) when APL is suspected rather than awaiting confirmatory tests with FISH. ATRA advances arrested promyeloblasts&#x000a0;into becoming mature granulocytes which can result in differentiation syndrome.<xref ref-type="bibr" rid="article-24207.r17">[17]</xref>&#x000a0;Differentiation syndrome is seen during 48 hours of ATRA initiation to even three weeks from starting therapy for APL. Patients have a fever, respiratory distress with acute pulmonary infiltration on imaging, and capillary leak resulting in edema. It can mimic sepsis,&#x000a0;resulting in delaying the treatment with dexamethasone. The commonly accepted starting dosage is 10mg every 12 hours till improvement in symptoms and counts.<xref ref-type="bibr" rid="article-24207.r18">[18]</xref>&#x000a0;Other significant complication with ATRA includes raised intracranial pressure leading to headaches and significant vision changes from papilledema.&#x000a0;</p>
        <p>Specific treatment for APL depends on whether the patient is at low or intermediate risk (also known as standard risk) with a WBC count &#x0003c;10,000/ mcL&#x000a0;or high risk with a WBC count &#x0003e;10,000/ mcL. Low or intermediate-risk APL is further differentiated by platelets above or below 40,000/mcL.</p>
        <list list-type="bullet">
          <list-item>
            <p>Standard-risk APL: Patients respond well to ATRA and arsenic trioxide (ATO) with lesser complications during induction and recovery&#x000a0;without needing an allogeneic stem cell transplant (SCT). During the utilization of ATO, patients need to be monitored for electrolyte changes closely and electrocardiogram for QTc prolongation changes(Framingham formula).<xref ref-type="bibr" rid="article-24207.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>High-risk APL: Along with ATRA + ATO, high-risk patients achieve better responses with the addition of idarubicin.<xref ref-type="bibr" rid="article-24207.r20">[20]</xref>&#x000a0;Recent studies have included&#x000a0;CD33-targeted drug conjugate, gemtuzumab ozogamicin (GO), during the induction therapy combined with ATRA + ATO.<xref ref-type="bibr" rid="article-24207.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>APL patients have better overall survival and prognosis than other types of AML without needing a transplant.&#x000a0;</p>
        <p><bold>AML: </bold>Standard therapy for AML is well known as the '7+3' regimen, which includes a 7-day course of cytarabine continuous infusion with a 3-day course of an anthracycline (either daunorubicin or idarubicin). With the advent of cytogenetics and NGS testing, patients are now being&#x000a0;risk-stratified based on the molecular markers&#x000a0;resulting in prognostic and therapeutic implications.<xref ref-type="bibr" rid="article-24207.r22">[22]</xref> The outline of therapy based on the risk status per ELN (European LeukemiaNet)&#x000a0;is as follows&#x000a0;</p>
        <table-wrap id="article-24207.table0" position="float" orientation="portrait">
          <table style="width: 1252.84px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="height: 13px; width: 95px;" rowspan="1" colspan="1">
<bold>Risk status</bold>
</td>
                <td style="height: 13px; width: 546px;" rowspan="1" colspan="1">
<bold>Cytogenetics</bold>
</td>
                <td style="height: 13px; width: 546px;" rowspan="1" colspan="1">
<bold>Treatment&#x000a0;</bold>
</td>
              </tr>
              <tr style="height: 40px;">
                <td style="height: 40px; width: 95px;" rowspan="1" colspan="1">Favorable risk</td>
                <td style="height: 40px; width: 546px;" rowspan="1" colspan="1">t(8;21)(q22;q22.1); inv(16) or t(16;16)Mutated NPM1 without FLT3-ITD or with FLT3-ITDlowBiallelic mutated CEBPA</td>
                <td style="height: 40px; width: 546px;" rowspan="1" colspan="1">
<p>Standard 7+3 regimen with/without GO.<xref ref-type="bibr" rid="article-24207.r23">[23]</xref></p>
<p>This chemo regimen can be attempted in patients &#x0003e; 60 years old if they have good tolerability as determined by performance status.&#x000a0;</p>
<p>Patients who achieve complete response can complete consolidation without the obvious need for SCT unless patients relapse.&#x000a0;</p>
</td>
              </tr>
              <tr style="height: 357.8px;">
                <td style="width: 95px; height: 357.8px;" rowspan="1" colspan="1">Intermediate risk</td>
                <td style="width: 546px; height: 357.8px;" rowspan="1" colspan="1">Mutated NPM1 and FLT3-ITD highWild type NPM1 without FLT3-ITD or with FLT3-ITD low (without adverse-risk genetic abnormalities)t(9;11)(p21.3;q23.3); MLLT3-KMT2ACytogenetic abnormalities not classified as favorable or adverse</td>
                <td style="width: 546px; height: 357.8px;" rowspan="1" colspan="1">
<p>Standard 7 + 3 with FLT3 tyrosine kinase inhibitor (midostaurin) during induction and consolidation.<xref ref-type="bibr" rid="article-24207.r24">[24]</xref></p>
<p>Strongly consider&#x000a0;SCT among this risk group.&#x000a0;</p>
<p><bold>For patients above 60 years or with intermediate performance status</bold></p>
<p>Hypomethylating agents (HMA) with/without B-cell lymphoma-2 (BCL-2) inhibitor - venetoclax.<xref ref-type="bibr" rid="article-24207.r25">[25]</xref></p>
<p><bold>Therapy-related AML or AML arising from antecedent&#x000a0;myelodysplastic syndrome&#x000a0;or Chronic myelomonocytic leukemia</bold></p>
<p>Patients respond better with liposomal cytarabine and daunorubicin, which is a category 1 indication in NCCN guidelines.<xref ref-type="bibr" rid="article-24207.r26">[26]</xref></p>
</td>
              </tr>
              <tr style="height: 122px;">
                <td style="height: 122px; width: 95px;" rowspan="1" colspan="1">Adverse risk</td>
                <td style="height: 122px; width: 546px;" rowspan="1" colspan="1">t(6;9)(p23;q34.1); DEK-NUP214t(v;11q23.3); KMT2A rearrangedt(9;22)(q34.1;q11.2); BCR-ABL1inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) &#x02013;5 or del(5q); &#x02013;7; &#x02013;17/abn(17p)Complex karyotype,&#x025ca; monosomal karyotype&#x000a7;Wild type NPM1 and FLT3-ITDhighMutated RUNX1Mutated ASXL1Mutated TP53</td>
                <td style="height: 122px; width: 546px;" rowspan="1" colspan="1">Clinical trials preferred</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>ALL</bold>
</p>
        <p>ALL is divided into B or T lymphocyte variants based on the lymphoblast origin and the presence of &#x0003e;20% lymphoblasts in peripheral smear or BM. The presence or absence of the Ph chromosome is the most important molecular marker&#x000a0;leading to therapeutic implications in treating ALL.&#x000a0;</p>
        <table-wrap id="article-24207.table1" position="float" orientation="portrait">
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>Ph status&#x000a0;</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Treatment regimen</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ph-positive ALL</td>
                <td rowspan="1" colspan="1">
<p>Combination of chemotherapy with oral tyrosine kinase inhibitor (TKI) favorably 2nd generation and beyond such as dasatinib, ponatinib, bosutinib, nilotinib, and imatinib. Not all the TKI combinations have data with chemotherapy agents, and the availability of the drug and provider practices generally dictate the regimen.&#x000a0;</p>
<p>For patients in adolescent and young adult (AYA) age groups (around 15&#x000a0;to 40 years), pediatric-inspired chemotherapy regimens with peg-asparaginase (Berlin-Frankfurt-M&#x000fc;nster regimen) are favored when patients can tolerate treatment.</p>
<p>Other chemotherapy options for patients &#x0003c;65 years old include hyper-fractionated CVAD(&#x000a0;cyclophosphamide, vincristine sulfate, doxorubicin, and dexamethasone), alternating with high-dose methotrexate and cytarabine, and newer therapy&#x000a0;with bispecific CD19-directed CD3 T-cell engager blinatumomab.<xref ref-type="bibr" rid="article-24207.r27">[27]</xref><xref ref-type="bibr" rid="article-24207.r28">[28]</xref><xref ref-type="bibr" rid="article-24207.r29">[29]</xref></p>
<p>For patients &#x0003e;65 years old, TKI backbone combined with&#x000a0;corticosteroids with/without vincristine or lower dose hyperCVAD&#x000a0;in robust patients can be tried.<xref ref-type="bibr" rid="article-24207.r30">[30]</xref><xref ref-type="bibr" rid="article-24207.r28">[28]</xref><xref ref-type="bibr" rid="article-24207.r30">[30]</xref></p>
<p>Recently a chemotherapy-free induction and consolidation regimen using dasatinib with blinatumomab yielded good responses and improved survival outcomes.<xref ref-type="bibr" rid="article-24207.r29">[29]</xref>&#x000a0;</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Ph negative ALL</td>
                <td rowspan="1" colspan="1">
<p>Chemotherapy forms the predominant backbone in Ph-negative patients without any role for TKIs. Multiple chemotherapy regimens are adapted based on the age of the patient.&#x000a0;</p>
<p>In AYA age&#x000a0;groups, predominant use of peg-asparaginase-based regimens such as CALGB 10403, COG AALL0434, DCFI ALL regimen,&#x000a0;etc.<xref ref-type="bibr" rid="article-24207.r31">[31]</xref><xref ref-type="bibr" rid="article-24207.r32">[32]</xref><xref ref-type="bibr" rid="article-24207.r33">[33]</xref></p>
<p>For patients less than 65 years old, rituximab-based regimens in CD20-positive patients, such as GRAALL-2005 <xref ref-type="bibr" rid="article-24207.r34">[34]</xref>, CALGB 8811, and hyperCVAD, as mentioned prior, are utilized.&#x000a0;</p>
<p>For older patients, based on their performance status, corticosteroids with/without vincristine, POMP regimen (prednisolone, vincristine, methotrexate, and 6-mercaptopurine),&#x000a0;and lower dose hyperCVAD therapy are options.<xref ref-type="bibr" rid="article-24207.r35">[35]</xref></p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The overall outcome depends upon the patient's response to induction&#x000a0;therapy&#x000a0;and the presence or absence of MRD (minimal residual disease) needing further therapies and BMT.&#x000a0;</p>
        <p><bold>CML:&#x000a0;</bold>CML is one of the first cancers revolutionized by utilizing targeted therapy with Ph chromosome targeting TKIs. Patients have a significant response to TKIs, negating the need for acute chemotherapy unless they are in an accelerated phase/blast crisis. A patient's risk can be assessed based on multiple available calculators such as the Sokal score, EUTOS Score, and EUTOS long-term survival score (ELTS).<xref ref-type="bibr" rid="article-24207.r36">[36]</xref><xref ref-type="bibr" rid="article-24207.r37">[37]</xref><xref ref-type="bibr" rid="article-24207.r38">[38]</xref>&#x000a0;For patients having high-risk disease, second-generation (nilotinib, dasatinib, and bosutinib) TKIs are utilized as first-line therapy to achieve the therapy milestones faster with deeper responses.<xref ref-type="bibr" rid="article-24207.r39">[39]</xref>&#x000a0;For low and intermediate-risk patients, imatinib can be&#x000a0;initiated as first-line therapy. However, there is no significant difference in overall survival based on the generation of the TKI used.&#x000a0;</p>
        <p>Major milestones after initiation of TKI include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>At 3 months: BCR-ABL1 [International Scale (IS)] at &#x02264;10 percent and/or &#x02264;35%&#x000a0;Ph-positive&#x000a0;metaphase cells</p>
          </list-item>
          <list-item>
            <p>At 6 months: BCR-ABL1 (IS) at &#x02264;1 percent or/and 0&#x000a0;% Ph-positive&#x000a0;metaphase cells</p>
          </list-item>
          <list-item>
            <p>At 1 year&#x000a0; &#x000a0; : BCR-ABL1 (IS) &#x02264;0.1 percent&#x000a0;</p>
          </list-item>
        </list>
        <p>Patients need to be monitored for resistance mutations, predominantly T315I mutation, for which ponatinib, asciminib, and omacetaxine are approved.<xref ref-type="bibr" rid="article-24207.r40">[40]</xref><xref ref-type="bibr" rid="article-24207.r41">[41]</xref>&#x000a0;Patients might&#x000a0;continue to develop resistance to multiple TKIs for whom&#x000a0;SCT can be attempted.&#x000a0;</p>
        <p><bold>CLL: </bold>CLL runs its course in a more indolent fashion than all the other leukemic subtypes, with the patient's lifespan minimally impacted by the disease. Patients do not benefit from early treatment unless they meet the criteria for therapy. Patients with a rapid doubling time of lymphocytes, worsening cytopenias, increasing spleen size causing abdominal discomfort, and significant B symptoms (fatigue, night sweats, and weight loss) benefit from treatment. The most important determinant in treating CLL is knowing the IGVH mutation status and the presence of del17p and TP53 mutation. t(11:14) is often obtained to rule out mantle cell lymphoma.&#x000a0;</p>
        <p>For patients with IGVH mutation who have a relatively good prognosis, chemotherapy with FCR (fludarabine, cyclophosphamide, rituximab)<xref ref-type="bibr" rid="article-24207.r42">[42]</xref> or BR (bendamustine, rituximab)<xref ref-type="bibr" rid="article-24207.r43">[43]</xref>&#x000a0;can be attempted as&#x000a0;patients would be able to achieve prolonged disease-free survival for over ten years. For high-risk patients with&#x000a0;del17p /&#x000a0;TP53 mutation, patients benefit significantly from targeted therapy with venetoclax (BCL-2 inhibitor) or Bruton's tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib), either as a single agent or in combination with rituximab or obinutuzumab.<xref ref-type="bibr" rid="article-24207.r44">[44]</xref><xref ref-type="bibr" rid="article-24207.r45">[45]</xref><xref ref-type="bibr" rid="article-24207.r46">[46]</xref><xref ref-type="bibr" rid="article-24207.r47">[47]</xref>&#x000a0;Older patients with comorbidities tolerate BTK inhibitors better.</p>
        <p>Rarely do patients with CLL/SLL who have a dormant course present with acute aggressive lymphadenopathy. They need an urgent lymph node or bone marrow biopsy to rule out&#x000a0;Richter transformation into aggressive&#x000a0;diffuse large B cell lymphoma and rarely Hodgkin lymphoma or T cell lymphomas.&#x000a0;</p>
      </sec>
      <sec id="article-24207.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis is broad because leukemia is a broad diagnosis with non-specific symptoms. One must rule out infection, drug effects, vitamin/micronutrient deficiencies, and other myelodysplastic disorders that can cause abnormalities in blood cell lines.&#x000a0;&#x000a0;</p>
        <p>Consider the following when seeing abnormalities in the blood count:</p>
        <list list-type="bullet">
          <list-item>
            <p>B12 and folate&#x000a0;deficiencies</p>
          </list-item>
          <list-item>
            <p>Copper&#x000a0;deficiencies</p>
          </list-item>
          <list-item>
            <p>Viral infections (e.g., HIV, cytomegalovirus, Epstein-Barr virus)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Drugs (chemotherapeutic agents, valproic acid, ganciclovir, mycophenolate mofetil)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Autoimmune conditions (e.g., systemic lupus erythematosus)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24207.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Long-term survival with leukemia varies tremendously based on leukemia subtype, cytogenetic and molecular findings, patient age, and comorbid conditions. Broadly, leukemia's 5-year cancer survival rate increased from 33% in 1975 to 59% in 2005.<xref ref-type="bibr" rid="article-24207.r6">[6]</xref></p>
      </sec>
      <sec id="article-24207.s12" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Tumor Lysis Syndrome (TLS)</bold>
</p>
        <p>TLS is a complication of chemotherapy that can result when tumor cells die quickly. The widespread cellular destruction releases intracellular contents into the bloodstream overwhelming the kidneys and resulting in dangerously high serum levels of potassium, phosphorus, and uric acid.<xref ref-type="bibr" rid="article-24207.r48">[48]</xref>&#x000a0;Patients need aggressive hydration, frequent lab monitoring, and management of hyperuricemia with allopurinol and rasburicase. Hyperkalemia and hypocalcemia can lead to significant cardiac toxicity requiring urgent correction.&#x000a0;</p>
        <p>
<bold>Disseminated Intravascular Coagulation (DIC)</bold>
</p>
        <p>DIC is a complication of leukemia itself in which the proteins that control the blood clotting process become dysfunctional, leading to both thrombosis and hemorrhage. DIC is often associated with acute promyelocytic leukemia but&#x000a0;can be seen in&#x000a0;other subtypes of leukemia as well.<xref ref-type="bibr" rid="article-24207.r16">[16]</xref>. Frequent lab monitoring with active replacement of fibrinogen with cryoprecipitate is vital to the patient's survival.&#x000a0;</p>
        <p>
<bold>Infection</bold>
</p>
        <p>Immunosuppression from chemotherapy, stem cell transplantation, or leukemia itself increases the risk of dangerous infections. Fever with neutropenia in an immunosuppressed patient should prompt an immediate evaluation for infection source and the initiation of broad-spectrum antibiotic therapy.<xref ref-type="bibr" rid="article-24207.r49">[49]</xref></p>
        <p>
<bold>Cancer</bold>
</p>
        <p>Survivors of leukemia are at an increased risk of subsequent cancers. For example, the Childhood Cancer Survivor Study demonstrated that the 30-year cumulative incidence of any cancer after leukemia was 5.6%; the median time to occurrence of the subsequent cancer was nine years. The most common second neoplasms in childhood leukemia survivors are different subtypes of leukemia or lymphoma.<xref ref-type="bibr" rid="article-24207.r10">[10]</xref></p>
      </sec>
      <sec id="article-24207.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Leukemia is the production of abnormal white blood cells from bone marrow and lymphatic tissues. Excess production of such white blood cells affects the production of normal blood cells, which are essential to fight infections, carry oxygen, and help clot blood. Such abnormal cell production can be fast, making it acute leukemia or a relatively slower process leading to chronic leukemia. Common symptoms include recurrent infections, weight loss, fatigue, fevers, abdominal pain, and&#x000a0;bleeding.&#x000a0;Multiple types of leukemias are present, and they require evaluation by a hematologist for further guidance on treatment.&#x000a0;</p>
      </sec>
      <sec id="article-24207.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Acute and chronic leukemias&#x000a0;are heterogeneous hematologic&#x000a0;diseases with complex diagnostic and therapeutic&#x000a0;implications requiring an interprofessional healthcare team. The involvement of&#x000a0;healthcare professionals from&#x000a0;across specialties and disciplines - clinicians, nurses, specialists (especially hematologists and oncologists), nurses, pharmacists, nutritionists, etc. - is&#x000a0;needed to&#x000a0;achieve effective management, mitigate adverse events, and&#x000a0;ensure their quality of life.</p>
        <p>The patient's&#x000a0;initial encounter&#x000a0;will often be with their family clinician, who runs initial bloodwork and other tests, but specialist input is an absolute necessity if there are any indications that leukemia is the diagnosis. Specialists will primarily guide the therapy regimen, but nursing will play a pivotal role in assisting in the evaluation, coordinating activities between specialists, and providing patient counseling. A specialized oncology pharmacist is a valuable asset to the team. Their consultation can help guide chemotherapy, appropriate dosing medication reconciliation, and medication counseling for patients, especially regarding adverse events. All interprofessional team members must maintain meticulous records on all interactions and interventions with the patient; this is part of communicating all patient data to the rest of the team. Everyone involved in care must keep other team members informed of any changes in the patient's condition as appropriate and include the patient in all care decisions, answering questions and offering counsel.&#x000a0;Patient-centered communication and shared decision-making are integral to successful patient outcomes in the interprofessional team model. [Level 5]</p>
      </sec>
      <sec id="article-24207.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24207&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24207">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/leukemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24207">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24207/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24207">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24207.s16">
        <fig id="article-24207.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Blast crisis, Leukemia, CML Contributed by Centers of Disease Control and Prevention (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="15271-microscopic-view-of-blast-crisis-of-chronic-myelogenous-leukemia-pv" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24207.s17">
        <fig id="article-24207.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Hairy cell leukemia Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hairycellL" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24207.s18">
        <fig id="article-24207.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Chronic Myeloid Leukemia.&#x000a0;Micrograph of a bone marrow biopsy of chronic myeloid leukemia showing hypercellularity and expansion of immature granulocytic paratrabecular cuff. Contributed by R Eden, DO</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="CML__BM__Myelopoiesis__and__Atypical__Megs" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24207.s19">
        <fig id="article-24207.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Image of leukemia cutis &#x00026; Immunophenotyping of leukemia cutis using CD markers Contributed by Shabir Bhimji, MD</p>
          </caption>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="leukemia__cutis__ppt.mp4" mime-subtype="mp4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-24207.s20">
        <fig id="article-24207.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Simplified hematopoiesis Contributed By A. Rad and M. H&#x000e4;ggstr&#x000f6;m. (CC-BY-SA 3.0 license https://creativecommons.org/licenses/by-sa/3.0/deed.en_US)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Hematopoiesis_simple.svg" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24207.s21">
        <title>References</title>
        <ref id="article-24207.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Le Beau</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vardiman</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2391</fpage>
            <page-range>2391-405</page-range>
            <pub-id pub-id-type="pmid">27069254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <article-title>Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>313</fpage>
            <pub-id pub-id-type="pmid">32767693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vardiman</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.</article-title>
            <source>Chem Biol Interact</source>
            <year>2010</year>
            <month>Mar</month>
            <day>19</day>
            <volume>184</volume>
            <issue>1-2</issue>
            <fpage>16</fpage>
            <page-range>16-20</page-range>
            <pub-id pub-id-type="pmid">19857474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunning</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Classification of acute leukemias.</article-title>
            <source>Semin Diagn Pathol</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>142</fpage>
            <page-range>142-53</page-range>
            <pub-id pub-id-type="pmid">14552428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.</article-title>
            <source>Cancer Causes Control</source>
            <year>2008</year>
            <month>May</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-90</page-range>
            <pub-id pub-id-type="pmid">18064533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer Statistics, 2017.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-30</page-range>
            <pub-id pub-id-type="pmid">28055103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bispo</surname>
                <given-names>JAB</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Kobetz</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and Etiology of Leukemia and Lymphoma.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2020</year>
            <month>Jun</month>
            <day>01</day>
            <volume>10</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">31727680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miranda-Filho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pi&#x000f1;eros</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soerjomataram</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Monnereau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological patterns of leukaemia in 184 countries: a population-based study.</article-title>
            <source>Lancet Haematol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>e14</fpage>
            <page-range>e14-e24</page-range>
            <pub-id pub-id-type="pmid">29304322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Leukemia and benzene.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>2875</fpage>
            <page-range>2875-93</page-range>
            <pub-id pub-id-type="pmid">23066403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Whitton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Leisenring</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stovall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Donaldson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Meadows</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Robison</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Neglia</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2010</year>
            <month>Jul</month>
            <day>21</day>
            <volume>102</volume>
            <issue>14</issue>
            <fpage>1083</fpage>
            <page-range>1083-95</page-range>
            <pub-id pub-id-type="pmid">20634481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Viera</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Leukemia: an overview for primary care.</article-title>
            <source>Am Fam Physician</source>
            <year>2014</year>
            <month>May</month>
            <day>01</day>
            <volume>89</volume>
            <issue>9</issue>
            <fpage>731</fpage>
            <page-range>731-8</page-range>
            <pub-id pub-id-type="pmid">24784336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stieglitz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Genetic predispositions to childhood leukemia.</article-title>
            <source>Ther Adv Hematol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>270</fpage>
            <page-range>270-90</page-range>
            <pub-id pub-id-type="pmid">23926459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leszczenko</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Borek-Dorosz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nowakowska</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Adamczyk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kashyrskaya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jakubowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Z&#x00105;bczy&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pastorczak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ostrowska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baranska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marzec</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Majzner</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Towards Raman-Based Screening of Acute Lymphoblastic Leukemia-Type B (B-ALL) Subtypes.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Oct</month>
            <day>31</day>
            <volume>13</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">34771646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Looi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zargari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dun</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grigoriadis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fedele</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>MSY</given-names>
              </name>
            </person-group>
            <article-title>Concomitant diagnosis of chronic myeloid leukaemia and myeloma.</article-title>
            <source>Pathology</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>493</fpage>
            <page-range>493-495</page-range>
            <pub-id pub-id-type="pmid">34776244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nebgen</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rhodes</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Munsell</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer.</article-title>
            <source>Obstet Gynecol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>128</volume>
            <issue>2</issue>
            <fpage>357</fpage>
            <page-range>357-363</page-range>
            <pub-id pub-id-type="pmid">27400009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Grimwade</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Lowenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fenaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Estey</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Naoe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lengfelder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>B&#x000fc;chner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lo-Coco</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Feb</month>
            <day>26</day>
            <volume>113</volume>
            <issue>9</issue>
            <fpage>1875</fpage>
            <page-range>1875-91</page-range>
            <pub-id pub-id-type="pmid">18812465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mantha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Zannino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Douer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Iland</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Litzow</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Geyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Laumann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Erba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Othus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Wiernik</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Mar</month>
            <day>30</day>
            <volume>129</volume>
            <issue>13</issue>
            <fpage>1763</fpage>
            <page-range>1763-1767</page-range>
            <pub-id pub-id-type="pmid">28082441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montesinos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bergua</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Vellenga</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ray&#x000f3;n</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Parody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de la Serna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le&#x000f3;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Esteve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Milone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Deb&#x000e9;n</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rivas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tormo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-Mediavilla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amutio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brunet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Jan</month>
            <day>22</day>
            <volume>113</volume>
            <issue>4</issue>
            <fpage>775</fpage>
            <page-range>775-83</page-range>
            <pub-id pub-id-type="pmid">18945964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lallemand-Breitenbach</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>de Th&#x000e9;</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Sep</month>
            <day>19</day>
            <volume>122</volume>
            <issue>12</issue>
            <fpage>2008</fpage>
            <page-range>2008-10</page-range>
            <pub-id pub-id-type="pmid">23894153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iland</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bradstock</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Supple</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Catalano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hertzberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Browett</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grigg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Firkin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hugman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di Iulio</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tiley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Filshie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Seldon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Szer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bashford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <collab>Australasian Leukaemia and Lymphoma Group</collab>
            </person-group>
            <article-title>All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Aug</month>
            <day>23</day>
            <volume>120</volume>
            <issue>8</issue>
            <fpage>1570</fpage>
            <page-range>1570-80; quiz 1752</page-range>
            <pub-id pub-id-type="pmid">22715121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abaza</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Garcia-Manero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Estey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Borthakur</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jabbour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faderl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brandt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCue</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luthra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kornblau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kadia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Daver</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>DiNardo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Verstovsek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferrajoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andreeff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Konopleva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Estrov</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Foudray</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCue</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ravandi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of acute promyelocytic leukemia treated with all-<italic>trans</italic>-retinoic acid, arsenic trioxide, and gemtuzumab.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Mar</month>
            <day>09</day>
            <volume>129</volume>
            <issue>10</issue>
            <fpage>1275</fpage>
            <page-range>1275-1283</page-range>
            <pub-id pub-id-type="pmid">28003274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Estey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grimwade</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amadori</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>B&#x000fc;chner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dombret</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Fenaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Lo-Coco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Naoe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Niederwieser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ossenkoppele</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sierra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Tien</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>L&#x000f6;wenberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Jan</month>
            <day>26</day>
            <volume>129</volume>
            <issue>4</issue>
            <fpage>424</fpage>
            <page-range>424-447</page-range>
            <pub-id pub-id-type="pmid">27895058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hills</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Castaigne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Delaunay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Petersdorf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Othus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Estey</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Dombret</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chevret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ifrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cahn</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>R&#x000e9;cher</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chilton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moorman</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Burnett</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>986</fpage>
            <page-range>986-96</page-range>
            <pub-id pub-id-type="pmid">25008258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlenk</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fiedler</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Salih</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Wulf</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Salwender</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kindler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>L&#x000fc;bbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kraemer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>G&#x000f6;tze</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Horst</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Krauter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Girschikofsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ringhoffer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000fc;dhoff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Derigs</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Schroers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grie&#x000df;hammer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Burchardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Martens</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hertenstein</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marretta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Heuser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thol</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gaidzik</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Herr</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Krzykalla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ganser</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paschka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <collab>German-Austrian AML Study Group</collab>
            </person-group>
            <article-title>Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <italic>FLT3</italic>-ITD.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Feb</month>
            <day>21</day>
            <volume>133</volume>
            <issue>8</issue>
            <fpage>840</fpage>
            <page-range>840-851</page-range>
            <pub-id pub-id-type="pmid">30563875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiNardo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Pullarkat</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thirman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Konopleva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Letai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fenaux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koller</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Havelange</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Leber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Esteve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pejsa</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>H&#x000e1;jek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porkka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ill&#x000e9;s</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Lavie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lemoli</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Turgut</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Potluri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pratz</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Aug</month>
            <day>13</day>
            <volume>383</volume>
            <issue>7</issue>
            <fpage>617</fpage>
            <page-range>617-629</page-range>
            <pub-id pub-id-type="pmid">32786187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolitz</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Strickland</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hogge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lancet</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Villa</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Chiarella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Louie</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>631</fpage>
            <page-range>631-640</page-range>
            <pub-id pub-id-type="pmid">31760835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slayton</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Kairalla</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Devidas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pulsipher</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Mullighan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iacobucci</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Heerema</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Gastier-Foster</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Mizrahy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Merchant</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Sieger</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Raetz</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Winick</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Hunger</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>36</volume>
            <issue>22</issue>
            <fpage>2306</fpage>
            <page-range>2306-2314</page-range>
            <pub-id pub-id-type="pmid">29812996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jabbour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Short</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Ravandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Daver</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>DiNardo</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Konopleva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pemmaraju</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Garcia-Manero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Garris</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jorgensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.</article-title>
            <source>Lancet Haematol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>e618</fpage>
            <page-range>e618-e627</page-range>
            <pub-id pub-id-type="pmid">30501869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fo&#x000e0;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bassan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vitale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Piciocchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Puzzolo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Canichella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lunghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fabbiano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bonifacio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fracchiolla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Di Bartolomeo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mancino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Propris</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Vignetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guarini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rambaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiaretti</surname>
                <given-names>S</given-names>
              </name>
              <collab>GIMEMA Investigators</collab>
            </person-group>
            <article-title>Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Oct</month>
            <day>22</day>
            <volume>383</volume>
            <issue>17</issue>
            <fpage>1613</fpage>
            <page-range>1613-1623</page-range>
            <pub-id pub-id-type="pmid">33085860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rousselot</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coud&#x000e9;</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gokbuget</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gambacorti Passerini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hayette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cayuela</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Huguet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leguay</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chevallier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salanoubat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonmati</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alexis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hunault</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glaisner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agape</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Berthou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jourdan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Banos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lioure</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ifrah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lafage-Pochitaloff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bornand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morisset</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pfeifer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Delannoy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ribera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bassan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Delord</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoelzer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dombret</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ottmann</surname>
                <given-names>OG</given-names>
              </name>
              <collab>European Working Group on Adult ALL (EWALL) group</collab>
            </person-group>
            <article-title>Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Aug</month>
            <day>11</day>
            <volume>128</volume>
            <issue>6</issue>
            <fpage>774</fpage>
            <page-range>774-82</page-range>
            <pub-id pub-id-type="pmid">27121472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stock</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Luger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Mullighan</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Willman</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Fulton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Laumann</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Malnassy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paietta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Geyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mr&#x000f3;zek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Sanford</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Marcucci</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liedtke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Claxton</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bogart</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Grecula</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Appelbaum</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Erba</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Litzow</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tallman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Apr</month>
            <day>04</day>
            <volume>133</volume>
            <issue>14</issue>
            <fpage>1548</fpage>
            <page-range>1548-1559</page-range>
            <pub-id pub-id-type="pmid">30658992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunsmore</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Winter</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Devidas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Esiashvili</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Eisenberg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Briegel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gastier-Foster</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Heerema</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Asselin</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Rabin</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Zweidler-Mckay</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Raetz</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Winick</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Hunger</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>38</volume>
            <issue>28</issue>
            <fpage>3282</fpage>
            <page-range>3282-3293</page-range>
            <pub-id pub-id-type="pmid">32813610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeAngelo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Dahlberg</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Couban</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Supko</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Amrein</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ballen</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Seftel</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Leber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Howson-Jan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Savoie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wadleigh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sirulnik</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Galinsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sallan</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.</article-title>
            <source>Leukemia</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>526</fpage>
            <page-range>526-34</page-range>
            <pub-id pub-id-type="pmid">25079173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Molica</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Rituximab in the management of acute lymphoblastic leukemia.</article-title>
            <source>Expert Opin Biol Ther</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-226</page-range>
            <pub-id pub-id-type="pmid">29310477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Pullen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vietti</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Fernbach</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia.</article-title>
            <source>Cancer</source>
            <year>1975</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>98</fpage>
            <page-range>98-102</page-range>
            <pub-id pub-id-type="pmid">1203854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokal</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tura</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gomez</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tso</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Clarkson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prognostic discrimination in "good-risk" chronic granulocytic leukemia.</article-title>
            <source>Blood</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-99</page-range>
            <pub-id pub-id-type="pmid">6584184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guilhot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saussele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guilhot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Porkka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ossenkoppele</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lindoerfer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Simonsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pfirrmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hehlmann</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Jul</month>
            <day>21</day>
            <volume>118</volume>
            <issue>3</issue>
            <fpage>686</fpage>
            <page-range>686-92</page-range>
            <pub-id pub-id-type="pmid">21536864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfirrmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saussele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guilhot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cervantes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ossenkoppele</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Castagnetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hasford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hehlmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Simonsson</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.</article-title>
            <source>Leukemia</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-56</page-range>
            <pub-id pub-id-type="pmid">26416462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vincelette</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Segar</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>e85</fpage>
            <page-range>e85-94</page-range>
            <pub-id pub-id-type="pmid">27101984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cortes</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Pinilla-Ibarz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>le Coutre</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Paquette</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chuah</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nicolini</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Apperley</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Talpaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>DeAngelo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Abruzzese</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baccarani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gambacorti-Passerini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lustgarten</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Haluska</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Guilhot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Deininger</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Hochhaus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Jul</month>
            <day>26</day>
            <volume>132</volume>
            <issue>4</issue>
            <fpage>393</fpage>
            <page-range>393-404</page-range>
            <pub-id pub-id-type="pmid">29567798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000e9;a</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mauro</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Boquimpani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Minami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lomaia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Voloshin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turkina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Apperley</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Abdo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fogliatto</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DDH</given-names>
              </name>
              <name>
                <surname>le Coutre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saussele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Annunziata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Chaudhri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chee</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Guti&#x000e9;rrez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Aimone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allepuz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quenet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B&#x000e9;doucha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hochhaus</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.</article-title>
            <source>Blood</source>
            <year>2021</year>
            <month>Nov</month>
            <day>25</day>
            <volume>138</volume>
            <issue>21</issue>
            <fpage>2031</fpage>
            <page-range>2031-2041</page-range>
            <pub-id pub-id-type="pmid">34407542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective.</article-title>
            <source>Curr Oncol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>30</day>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>3825</fpage>
            <page-range>3825-3835</page-range>
            <pub-id pub-id-type="pmid">34677244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bahlo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Busch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>K&#x000f6;ppler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kiehl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000f6;kler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schlag</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vehling-Kaiser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>K&#x000f6;chling</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pl&#x000f6;ger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gregor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Plesner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trneny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>D&#x000f6;hner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kneba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Klapper</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kreuzer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ttcher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <collab>international group of investigators</collab>
              <collab>German CLL Study Group (GCLLSG)</collab>
            </person-group>
            <article-title>First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>928</fpage>
            <page-range>928-942</page-range>
            <pub-id pub-id-type="pmid">27216274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharman</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Egyed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Skarbnik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pagel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Kamdar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Munir</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Walewska</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fogliatto</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Herishanu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Follows</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ghia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cymbalista</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Woyach</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Munugalavadla</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2020</year>
            <month>Apr</month>
            <day>18</day>
            <volume>395</volume>
            <issue>10232</issue>
            <fpage>1278</fpage>
            <page-range>1278-1291</page-range>
            <pub-id pub-id-type="pmid">32305093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Sawaf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Robrecht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Samoylova</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Liberati</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pinilla-Ibarz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Opat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sivcheva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Le D&#x000fb;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fogliatto</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Niemann</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Weinkove</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Tausch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schary</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ritgen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wendtner</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kreuzer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Eichhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>1188</fpage>
            <page-range>1188-1200</page-range>
            <pub-id pub-id-type="pmid">32888452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreno</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Greil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Demirkan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Larratt</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Simkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samoilova</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ben-Yehuda</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Strugov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gribben</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lih</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clow</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Styles</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>IW</given-names>
              </name>
            </person-group>
            <article-title>Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-56</page-range>
            <pub-id pub-id-type="pmid">30522969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Mittmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Owen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Abdel-Samad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>GAM</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crump</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sperlich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van der Jagt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prica</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Couban</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Woyach</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ruppert</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Mandrekar</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>766</fpage>
            <page-range>766-774</page-range>
            <pub-id pub-id-type="pmid">34334330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Trifilio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.</article-title>
            <source>Ann Hematol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>563</fpage>
            <page-range>563-73</page-range>
            <pub-id pub-id-type="pmid">26758269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24207.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freifeld</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Bow</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Sepkowitz</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Boeckh</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Raad</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Rolston</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wingard</surname>
                <given-names>JR</given-names>
              </name>
              <collab>Infectious Diseases Society of Americaa</collab>
            </person-group>
            <article-title>Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Feb</month>
            <day>15</day>
            <volume>52</volume>
            <issue>4</issue>
            <fpage>427</fpage>
            <page-range>427-31</page-range>
            <pub-id pub-id-type="pmid">21205990</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
